Investor Presentaiton

Investor presentation First three months of 2017 Slide 51 Continued expansion of the modern insulin market in China Chinese insulin market by segments Chinese total insulin value market shares Device penetration Modern Insulin penetration Novo Nordisk Sanofi bDKK Penetration Gan & Lee Tonghua Dongbao Eli Lilly United Lab 8 CAGR value¹: 19.8% 100% 70% Fast-acting 60% 80% 6 50% 51% 60% Premix 40% 4 40% 30% 20% 2 20% Long-acting 10% 0% 0% Feb 2012 1 CAGR for 5-year period Note: IMS covers around 50% of the total Chinese market (hospital data) Source: IMS Rolling MAT February, 2017 value (DKK) figures Feb 2017 Feb 2012 17% 11% 6% 1% Feb 2017 Note: Only selected competitors Source: IMS Rolling MAT February, 2017 value figures, numbers do not add up to 100% due to smaller insulin manufacturers not included changing diabetes® novo nordisk

View entire presentation